Teriflunomide: A Once-Daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis

    September 2015 in “ Clinical Therapeutics ”
    Aaron Miller
    Studysummary This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on clinicaltherapeutics.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Teriflunomide and Its Mechanism of Action in Multiple Sclerosis Drugs · 2014